Relationships of hormones of adipose tissue and ghrelin to bone metabolism
Authors:
I. Žofková
Authors‘ workplace:
Endokrinologický ústav Praha, ředitel doc. MUDr. Vojtěch Hainer, CSc.
Published in:
Vnitř Lék 2009; 55(6): 560-564
Category:
Reviews
Overview
Body adipose tissue influences bone metabolism through mechanical load, as well as via hormones released into circulation. Such hormones are adipocytokines – leptin, adiponectin, TNF‑α, IL‑6, resistin and visfatin. Some of them exert an osteoanabolic effect, while the others activate bone resorption. An increasingly discussed adipocytokine is leptin, which fundamental role is regulation of food intake ensuring survival of the organism during starvation. Leptin also stimulates osteoblasts and activates bone formation. The direct osteotropic effect of leptin is modulated by interaction with hypothalamic centers and neurohormones. Apparently, the most important leptin sensitive pathway involved in bone regulation is the beta‑adrenergic system. While activation of β-1‑adrenergic receptors by leptin enhances bone formation, activation of β-2‑adrenergic receptors in hypothalamus and in the skeleton increases bone resorption. In humans, an anabolic effect on the skeleton prevails. In pubertal girls, leptin extensively released into circulation at the moment when adipose tissue reaches a critical volume, stimulates synthesis of GnRH and induces puberty, which is followed by striking increases in bone mass. Low leptin levels in anorexia nervosa are associated with amenorrhoea, which slows down increase of bone mass and may induce osteopenia. Important adipocytokine with an unambiguous negative effect on bone is adiponectin. Decreased production of this hormone explains in part the lower prevalence of osteoporosis in obese persons. In this article, the osteotropic importance of leptin‑sensitive neurohormonal mechanisms and other hormones related to adipose tissue are discussed. Clinical importance of the above mentioned hormones to integrity of the skeleton has not yet been verified.
Key words:
adipose tissue – bone – leptin – adiponectin – β‑adrenergic system – ghrelin – pubertal bone
Sources
1. Ahima RS, Osei SY. Adipokines in obesity. Front Horm Res 2008; 36: 182–197.
2. Baldock PA, Allison S, McDonald MM et al. Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 2006; 21: 1600–1607.
3. Bartell SM, Isales CM, Baile CA et al. CART deficiency increases body weight but does not alter bone strength. J Musculoskelet Neuronal Interact 2008; 8: 146–153.
4. Bjørbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004; 59: 305–331.
5. Bonnet N, Pierroz DD, Ferrari SL. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact 2008; 8: 94–104.
6. Bronský J, Kotaska K, Průša R. Ghrelin – structure, function and clinical applications. Česk Fyziol 2004; 53: 80–85.
7. Caetano-Lopes J, Canhão H, Fonseca JE. Osteoblasts and bone formation. Acta Rheumatol Port 2007; 32: 103–110.
8. Carrasco F, Ruz M, Rojas P et al. Changes in bone mineral density, body composition and adiponectin levels in morbidly obese patients after bariatric surgery. Obes Surg 2009; 19: 41–46.
9. Castellano JM, Roa J, Luque RM et al. KiISS-1/kisspeptins and the metabolic control of reproduction: physiologic roles and putative physiopathological implications. Peptides 2009; 30: 139–145.
10. Ealey KN, Kaludjerovic J, Archer MC et al. Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 2008; 233: 1546–1553.
11. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 2008; 473: 231–236.
12. Fairbrother UL, Tankó LB, Halley AJ et al. Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res 2007; 22: 544–550.
13. Fonseca-Alaniz MH, Takada J, Alonso-Vale MI et al. Adipose tissue as an endocrine organ: from theory to practice. J Pediatr (Rio J)2007; 83 (Suppl 5): S192–S203.
14. Golden NH, Carlson JL. The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci 2008; 1135: 163–178.
15. Gonnelli S, Caffarelli C, Del Santo K et al. The relationship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men. Calcif Tissue Int 2008; 83: 55–60.
16. Hamrick MW, Ferrari SL. Leptin and the sympathetic connection of fat to bone. Osteoporosis Int 2008; 19: 905–912.
17. Holmen SL, Zylstra CR, Mukherjee A et al. Essential role of beta‑catenin in postnatal bone acquisition. J Biol Chem 2005; 280: 21162–21168.
18. Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379–388.
19. Jürimäe J, Jürimäe T, Leppik A et al. The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab 2008; 26: 618–623.
20. Kaplowitz PB. Link between body fat and timing of puberty. Pediatrics 2008; 121 (Suppl 3): S208–S217.
21. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin‑the classical, resistin‑the controversial, adiponectin‑the promissing, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525–546.
22. Koh JM, Kim DJ, Hong JS et al. Estrogen receptor alpha gene polymorphisms Pvu II and Xba I influence association between leptin receptor gene polymorphism (Gln223Arg) and bone mineral density in young men. Eur J Endocrinol 2002; 147: 777–783.
23. Kršek M, Rosická M, Haluzík M et al. The changes in serum ghrelin levels and their relationship to IGF‑I, its binding proteins and leptin in women patiens with anorexia nervosa. Vnitř Lék 2002; 48: 948–951.
24. Lac G, Cavalie H, Ebal E et al. Effects of a high fat diet on bone of growing rats. Correlations between visceral fat, adiponectin and bone mass density. Lipids Health Dis 2008; 7: 16.
25. Lerner UH, Persson E. Osteotropic effects by the neuropeptides calcitonin gene‑related peptide, substance P and vasoactive intestinal peptide. J Musculoskelet Neuronal Interact 2008; 8: 154–165.
26. Makovey J, Naganathan V, Seidel M et al. Gender differences in plasma ghrelin and its relations to body composition and bone – an opposite-sex twin study. Clin Endocrinol (Oxford) 2007; 66: 530–537.
27. Misra M, Miller KK, Kuo K et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005; 289: E347–E356.
28. Misra M, Miller KK, Cord J et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endocrinol Metab 2007; 92: 2046–2052.
29. Morelli A, Marini M, Mancina R et al. Sex steroids and leptin regulates the „first Kiss“ (KiSS 1/G-protein‑coupled receptor 54 system) in human gonadotropin‑releasing-hormone-secreting neuroblasts. J Sex Med 2008; 5: 1097–1113.
30. Matkovic V, Ilich J, Skugor M et al. Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 1997; 82: 3239–3245.
31. Oh KW, Lee WY, Rhee EJ et al. The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 2005; 63: 131–138.
32. Peng XD, Xie H, Zhao Q et al. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 2008; 387: 31–35.
33. Pierroz DD, Bouxsein ML, Rizzoli R et al. Combined treatment with a beta‑blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice. Bone 2006; 39: 260–267.
34. Popovic V, Duntas LH. Leptin, TRH and ghrelin: influence on energy homeostasis at rest and during exercise. Horm Metab Res 2005; 37: 533–537.
35. Qui Y, Sun X, Qui X et al. Decreased circulating leptin levels and its association with body and bone mass in girls with adolescent idiopathic scoliosis. Spine 2007; 32: 2703–2710.
36. Richert L, Chevalley T, Manen D et al. Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J Clin Endocrinol Metab 2007; 92: 4380–4386.
37. Scariano JK, Garry PJ, Montoya GD et al. Serum leptin levels, bone mineral density and osteoblast alkaline phosphatase activity in elderly men and women. Mech Ageing Dev 2003; 124: 281–286.
38. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349–3354.
39. Suzuki N, Somei M, Kitamura K et al. Novel bromomelatonin derivatives suppress osteoclastic activity and increase osteoblastic activity: implications for the treatment of bone diseases. J Pineal Res 2008; 44: 326–334.
40. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 2004; 4: 295–300.
41. Thommesen L, Stunes AK, Monjo M et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 2006; 99: 824–834.
42. Zoico E, Zamboni M, Di Francesco V et al. Relation between adiponectin and bone mineral density in elderly postmenopausal women: role of body composition, leptin, insulin resistance, and dehydroepiandrosterone sulfate. J Endocrinol Invest 2008; 31: 297–302.
43. Žofková I. Hormonal aspects of the muscle-bone unit. Physiol Res 2008; 57 (Suppl 1): S159–S169.
44. Žofková I, Hill M. Biochemical markers of bone remodeling correlate negatively with circulating TSH in postmenopausal women. Endocr Regul 2008; 42: 121–127.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
![Issue 6](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/b5aae6ba53721a0c0148619ce6478982.jpeg)
2009 Issue 6
Most read in this issue
- The treatment of renal failure in multiple myeloma
- Is confirmation of an adrenal adenoma in patients with primary aldosteronism sufficient for indication of adrenalectomy?
- Venous thromboembolism in an oncology patient
- Application of warfarin pharmacogenetics